`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`TEVA PHARMACEUTICALS USA, INC.
`Petitioner
`
`V.
`
`CORCEPT THERAPEUTICS, INC.
`Patent Owner
`
`Case No: Unassigned
`US. Patent No. 10,195,214
`
`Title: CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID
`
`RECEPTOR MODULATORS AND CYP3A INHIBITORS
`
`DECLARATION OF ATUL KAUSHIK
`
`TEVA1 054
`
`TEVA1054
`
`
`
`Petition for Post-Grant Review
`
`US. Patent No. 10,195,214
`Declaration of Atul Kaushik
`
`I, Atul Kaushik, hereby declare as follows:
`
`1.
`
`I am over the age of eighteen (18) and competent to make this
`
`declaration.
`
`2.
`
`I understand that this Declaration accompanies a petition for PGR
`
`involving US. Patent No. 10,195,214 (“the ’214 patent”) (TEVA1001).
`
`'3.
`
`I have personal knowledge of all the facts contained in this
`
`declaration.
`
`4.
`
`I am Senior Director at Teva Pharmaceuticals USA, Inc. My business
`
`address is Plot No. K-7, MIDC, Additional Ambernath (E), Dist-Thane, India—
`
`421506. In this role, I am leading Formulation Research and Development
`
`Department. As part of my duties, I routinely review FDA approval packages for
`
`branded drugs for which Teva seeks FDA approval to manufacture and distribute a
`
`generic equivalent. 1, or one of my colleagues at Teva, access these materials by
`
`downloading them from the FDA’s website.
`
`5.
`
`On December 15, 2017, Teva filed Abbreviated New Drug
`
`Application No. 211436 seeking to market a generic version of Korlym®
`
`(mifepristone) Tablets, 300 mg. Korlym is the subject of Corcept Therapeutic,
`
`Inc.’s New Drug Application No. 202107, which was approved by the FDA on
`
`February 17, 2012.
`
`
`
`Petition for Post-Grant Review
`
`US. Patent No. 10,195,214
`Declaration of Atul Kaushik
`
`6.
`
`In April 2016, in connection with Teva’s preparation of ANDA No.
`
`211436, my colleague Pritesh Jain downloaded all the materials in the Drug \
`
`Approval Package for Korlym from the FDA’s website. See
`
`https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107_korlym_toc.cf
`
`m. This webpage’s “Date created” is listed as July 6, 2012. I know that Mr. Jain
`
`downloaded the material in early 2016 because it was part of our preparation of
`
`ANDA No. 211436. The documents from the Korlym Drug Approval Package
`
`Were electronically saved on Teva’s internal network in April 2016, as shown in
`
`the screenshot below, which I took on April 26, 2019.
`
` om v
`
`3': anm
`I Dump
`3 Downloads
`’5‘ Rennntpllcu
`
`‘3' Limn'u
`*1 Documents
`Jr Music
`g Plcmlu
`I Wdem
`fl Computzv
`L OSan (ca
`g Corp_QA (\\Tm.Cc
`fi Nth-ark
`
`, 7
`
`v”
`
`mum um
`\\1U,m§3,2|\v|bfi:\PUBLIE\FRD\..
`24mm
`EDI/2016450554
`W’N‘S‘EW
`"
`31:“
`WWW
`102029321
`
`‘
`‘;
`E
`i
`
`;
`'
`
`lapmwmummnuaum7 v
`”"ne
`
`5 REMS Rawxfiles
`7—"??5- .
`7
`,, 3"“ .
`1‘ ZUZWTOIIgleflAdm.........pdf
`'1’ 2121010dgb000Chemedf
`fizz-11M ”*5" swim; ..
`'1‘ 2021Mo¢iglxfloflcIinpharmnpdf
`’
`'
`'
`3‘ ZJZlfllOngbUWClouR-pdf
`'1’ Zfll‘flYOnghflflOMszpdf
`1' 202m10n51xoflflNamedef
`'1‘ 2021010ri9b|7000fllstpdf
`{1‘ ZflZmTOIighWflOthuflqadf
`3f ZDZLDTOIiglsfllehamRPdf
`'1‘ ZflZmlOnglsflfloRirklpdf
`5‘ 2021070rig130005hlkpdf
`'1' lflZmTOngbVflDSuprdf
`1' lflllflhflflfllblpdf
`'1‘ 2nziovsanom.paf
`'1‘ Dairy med L:be|.pcf
`1‘ Pllpdf
`8:: “EMS sumsmm
`
`
`
`
`..
`
`x
`
`,
`..
`
`2'4
`
`iIl
`
`mum 4.50 PM
`urea/2
`'~ '
`
`
`
`.5
`
`m VILpdf
`cm meadim BAN/2016 4:50 ”A
`On: :reoLett zmmois .250 PM
`}».
`c 2 ‘:m
`, m
`34:? no KB
`C’fflmeaxafizbilfif. Notwiflable
`A._,
`
`
`Offlin: mm: On‘m
`
`I
`
`
`
`Petition for Post-Grant Review
`
`US. Patent No. 10,195,214
`
`Declaration of Atul Kaushik
`
`7.
`
`The file named “202107sOOOlbl.pdf” is a copy of the original FDA-
`
`approved label for Korlym that was downloaded from the FDA website. I confirm
`
`that Mr. Jain downloaded “202107sOOOlbl.pdf” in April 2016 as a part of the
`
`preparation for Teva’s filing ANDA No. 211436. This document is attached to
`
`Teva’s petition as Exhibit TEVA1004.
`
`8.
`
`The file named “202107orig1sOOOclinpharmrpdf’ is copy of the
`
`Clinical Pharmacology Review for Korlym, Office of Clinical Pharmacology
`
`Review NDA 20687 (Addendum, KorlymTM, Mifepristone) (2012) that was
`
`downloaded from the FDA website. I confirm that Mr. Jain downloaded
`
`“202107orig1sOOOclinpharmrpdf’ in April 2016 as a part of the preparation for
`
`Teva’s filing ANDA No. 211436. This document is attached to Teva’s petition as
`
`Exhibit TEVA1005.
`
`9.
`
`The file named “20210730001tr.pdf” is a copy of FDA’s approval
`
`letter for Korlym that was downloaded from the FDA website. I confirm that Mr.
`
`Jain downloaded “20210730001tr'.pdf’ in April 2016 as a part of the preparation for
`
`Teva’s filing ANDA No. 211436. This document is attached to Teva’s petition as
`
`Exhibit TEVAl 006.
`
`
`
`Petition for Post-Grant Review
`
`US. Patent No. 10,195,214
`Declaration of Atul Kaushik
`
`10.
`
`I accordingly have personal knowledge that the documents attached to
`
`Teva’s petition as Exhibits TEVA1004, TEVA1005, and TEVA1006 were publicly
`
`available on the FDA’s website no later than April 2016.
`
`I hereby declare that all statements made herein of my own knowledge are
`
`true and that all statements made on information and belief are believed to be true,
`
`and further that these statements were made with the knowledge that willful false
`
`statements and the like so made are punishable by fine or imprisonment, or both,
`
`under Section 1001 of Title 18 of the United States Code.
`
`Respectfully submitted,
`
`OW/
`
`Atul Kaushik
`
`[Senior Director-FRD]
`
`Date: May 7, 2019
`
`